Drug Profile
Betamethasone diproprionate/calcipotriol - LEO Pharma
Alternative Names: Cal/BD foam - Leo Pharma; Calcipotriene/betamethasone propionate; Calcipotriol/betamethasone diproprionate; Daivobet; Daivobet 50/500 Ointment; Daivobet Gel; Dovobet; Enstilar; LEO 90105; LEO-80185; LEO-90100; LEO90100 cutaneous spray; LP-0113; Taclonex; Taclonex Scalp; XamiolLatest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator LEO Pharma
- Developer Kyowa Kirin; LEO Pharma
- Class Anti-inflammatories; Antiallergics; Antipsoriatics; Cyclohexenes; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Indenes; Small molecules; Vitamin D analogues
- Mechanism of Action Calcitriol receptor agonists; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Plaque psoriasis; Psoriasis
Most Recent Events
- 05 Mar 2024 LEO Pharma completes phase III trial for Plaque psoriasis in China (Topical) (NCT05919082)
- 29 Jun 2023 LEO Pharma plans a phase III trial for Plaque psoriasis in China (Topical) (NCT05919082)
- 21 Jun 2023 LEO Pharma initiates phase III trial for Plaque psoriasis in China (Topical) (NCT05919082)